evaluate(model, log = list(level=1,type='html'))
Running Model:
Reading in Tabular Data:
AE_costs:
|
AE
|
Cost
|
|
Lymphopenia
|
167
|
|
ALT increased
|
376
|
|
Cholelithiasis
|
4427
|
|
Influenza
|
5013
|
|
Serious infection
|
10251
|
|
Trigeminal neuralgia
|
7858
|
|
Depression
|
4224
|
|
PML
|
30591
|
AE_disutilities:
|
AE
|
Utility
|
|
Lymphopenia
|
0.000
|
|
ALT Increased
|
0.000
|
|
Cholelithiasis
|
-0.005
|
|
Influenza
|
-0.016
|
|
Serious Infection
|
-0.005
|
|
Trigeminal Neuralgia
|
-0.440
|
|
Depression
|
-0.560
|
|
PML
|
-0.400
|
AE_Incidence_2L:
|
AE
|
Lymphopenia
|
ALT Increased
|
Cholelithiasis
|
Influenza
|
Serious Infection
|
Trigeminal Neuralgia
|
Depression
|
PML
|
|
Siponimod
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
|
Alemtuzumab
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
|
Dimethyl fumarate
|
0.00
|
0.00
|
0.00
|
0.00
|
0.01
|
0.00
|
0.00
|
0e+00
|
|
Fingolimod
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
|
Glatiramer acetate
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
|
Rebif 22
|
0.01
|
0.00
|
0.01
|
0.01
|
0.00
|
0.01
|
0.01
|
0e+00
|
|
Rebif 44
|
0.01
|
0.00
|
0.01
|
0.01
|
0.00
|
0.01
|
0.01
|
0e+00
|
|
Avonex
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
|
Betaferon
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
|
Peginterferon beta-1a
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
|
Natalizumab
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
3e-04
|
|
Teriflunomide (7mg)
|
0.00
|
0.01
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
|
Teriflunomide (14mg)
|
0.00
|
0.01
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
|
Ocrelizumab
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
|
Supportive care
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0e+00
|
AE_incidence_one_off:
|
AE
|
Siponimod
|
Alemtuzumab
|
Dimethyl fumarate
|
Fingolimod
|
Glatiramer acetate
|
Rebif 22
|
Rebif 44
|
Avonex
|
Betaferon
|
Peginterferon beta-1a
|
Natalizumab
|
Teriflunomide (7mg)
|
Teriflunomide (14mg)
|
Ocrelizumab
|
Supportive care
|
|
Lymphopenia
|
0
|
0
|
0.00
|
0
|
0
|
0.01
|
0.01
|
0
|
0
|
0
|
0e+00
|
0.00
|
0.00
|
0
|
0
|
|
ALT Increased
|
0
|
0
|
0.00
|
0
|
0
|
0.00
|
0.00
|
0
|
0
|
0
|
0e+00
|
0.01
|
0.01
|
0
|
0
|
|
Cholelithiasis
|
0
|
0
|
0.00
|
0
|
0
|
0.01
|
0.01
|
0
|
0
|
0
|
0e+00
|
0.00
|
0.00
|
0
|
0
|
|
Influenza
|
0
|
0
|
0.00
|
0
|
0
|
0.01
|
0.01
|
0
|
0
|
0
|
0e+00
|
0.00
|
0.00
|
0
|
0
|
|
Serious Infection
|
0
|
0
|
0.01
|
0
|
0
|
0.00
|
0.00
|
0
|
0
|
0
|
0e+00
|
0.00
|
0.00
|
0
|
0
|
|
Trigeminal Neuralgia
|
0
|
0
|
0.00
|
0
|
0
|
0.01
|
0.01
|
0
|
0
|
0
|
0e+00
|
0.00
|
0.00
|
0
|
0
|
|
Depression
|
0
|
0
|
0.00
|
0
|
0
|
0.01
|
0.01
|
0
|
0
|
0
|
0e+00
|
0.00
|
0.00
|
0
|
0
|
|
PML
|
0
|
0
|
0.00
|
0
|
0
|
0.00
|
0.00
|
0
|
0
|
0
|
3e-04
|
0.00
|
0.00
|
0
|
0
|
Discontinuation:
|
Regimen
|
Year 1
|
Year 2+
|
|
Siponimod
|
0.094
|
0.094
|
|
Alemtuzumab
|
0.023
|
0.023
|
|
Dimethyl fumarate
|
0.133
|
0.133
|
|
Fingolimod
|
0.084
|
0.084
|
|
Glatiramer acetate
|
0.052
|
0.052
|
|
Rebif 22
|
0.056
|
0.056
|
|
Rebif 44
|
0.086
|
0.086
|
|
Avonex
|
0.053
|
0.053
|
|
Betaferon
|
0.044
|
0.044
|
|
Peginterferon beta-1a
|
0.049
|
0.049
|
|
Natalizumab
|
0.049
|
0.049
|
|
Teriflunomide (7mg)
|
0.123
|
0.123
|
|
Teriflunomide (14mg)
|
0.127
|
0.127
|
|
Ocrelizumab
|
0.050
|
0.050
|
|
Supportive care
|
0.000
|
0.000
|
EDSS_costs:
|
EDSS
|
Direct costs
|
Indirect costs
|
|
RRMS 0
|
2825
|
10711
|
|
RRMS 1
|
4856
|
14653
|
|
RRMS 2
|
6887
|
18595
|
|
RRMS 3
|
8917
|
22537
|
|
RRMS 4
|
10948
|
26480
|
|
RRMS 5
|
12979
|
30422
|
|
RRMS 6
|
15010
|
34364
|
|
RRMS 7
|
17041
|
38306
|
|
RRMS 8
|
19071
|
42249
|
|
RRMS 9
|
21102
|
46191
|
|
SPMS 0
|
2825
|
10711
|
|
SPMS 1
|
4856
|
14653
|
|
SPMS 2
|
6887
|
18595
|
|
SPMS 3
|
8917
|
22537
|
|
SPMS 4
|
10948
|
26480
|
|
SPMS 5
|
12979
|
30422
|
|
SPMS 6
|
15010
|
34364
|
|
SPMS 7
|
17041
|
38306
|
|
SPMS 8
|
19071
|
42249
|
|
SPMS 9
|
21102
|
46191
|
EDSS_RR_mortality:
|
EDSS
|
RR
|
|
0
|
1.00
|
|
1
|
1.43
|
|
2
|
1.60
|
|
3
|
1.64
|
|
4
|
1.67
|
|
5
|
1.84
|
|
6
|
2.27
|
|
7
|
3.10
|
|
8
|
4.45
|
|
9
|
6.45
|
EDSS_Utilities:
|
EDSS
|
RRMS Utility
|
SPMS Utility
|
|
0
|
0.8752
|
1.0000
|
|
1
|
0.8342
|
0.7905
|
|
2
|
0.7802
|
0.7365
|
|
3
|
0.6946
|
0.6509
|
|
4
|
0.6253
|
0.5816
|
|
5
|
0.5442
|
0.5005
|
|
6
|
0.4555
|
0.4118
|
|
7
|
0.3437
|
0.3000
|
|
8
|
0.0023
|
-0.0413
|
|
9
|
-0.1701
|
-0.2138
|
Monitoring_costs:
|
Regimen
|
Year 1
|
Year 2+
|
|
Siponimod
|
175.00
|
0.00
|
|
Alemtuzumab
|
0.00
|
0.00
|
|
Dimethyl fumarate
|
58.54
|
38.36
|
|
Fingolimod
|
337.80
|
155.44
|
|
Glatiramer acetate
|
0.00
|
0.00
|
|
Rebif 22
|
118.08
|
78.72
|
|
Rebif 44
|
118.08
|
78.72
|
|
Avonex
|
118.08
|
78.72
|
|
Betaferon
|
118.08
|
78.72
|
|
Peginterferon beta-1a
|
78.72
|
78.72
|
|
Natalizumab
|
1047.28
|
1047.28
|
|
Teriflunomide (7mg)
|
117.84
|
0.00
|
|
Teriflunomide (14mg)
|
117.84
|
0.00
|
|
Ocrelizumab
|
0.00
|
0.00
|
|
Supportive care
|
0.00
|
0.00
|
Mortality_table:
|
age
|
male
|
female
|
|
0
|
0.006575
|
0.005516
|
|
1
|
0.000445
|
0.000382
|
|
2
|
0.000301
|
0.000225
|
|
3
|
0.000240
|
0.000175
|
|
4
|
0.000183
|
0.000151
|
|
5
|
0.000169
|
0.000132
|
|
6
|
0.000150
|
0.000117
|
|
7
|
0.000134
|
0.000106
|
|
8
|
0.000115
|
0.000096
|
|
9
|
0.000097
|
0.000088
|
|
10
|
0.000085
|
0.000084
|
|
11
|
0.000092
|
0.000087
|
|
12
|
0.000132
|
0.000102
|
|
13
|
0.000213
|
0.000129
|
|
14
|
0.000323
|
0.000166
|
|
15
|
0.000439
|
0.000207
|
|
16
|
0.000552
|
0.000247
|
|
17
|
0.000675
|
0.000286
|
|
18
|
0.000807
|
0.000320
|
|
19
|
0.000942
|
0.000351
|
|
20
|
0.001085
|
0.000384
|
|
21
|
0.001216
|
0.000416
|
|
22
|
0.001310
|
0.000445
|
|
23
|
0.001353
|
0.000467
|
|
24
|
0.001358
|
0.000486
|
|
25
|
0.001351
|
0.000505
|
|
26
|
0.001349
|
0.000526
|
|
27
|
0.001353
|
0.000553
|
|
28
|
0.001371
|
0.000587
|
|
29
|
0.001399
|
0.000627
|
|
30
|
0.001432
|
0.000673
|
|
31
|
0.001464
|
0.000721
|
|
32
|
0.001496
|
0.000766
|
|
33
|
0.001528
|
0.000805
|
|
34
|
0.001563
|
0.000842
|
|
35
|
0.001613
|
0.000888
|
|
36
|
0.001682
|
0.000947
|
|
37
|
0.001764
|
0.001017
|
|
38
|
0.001857
|
0.001099
|
|
39
|
0.001964
|
0.001192
|
|
40
|
0.002083
|
0.001291
|
|
41
|
0.002227
|
0.001402
|
|
42
|
0.002414
|
0.001535
|
|
43
|
0.002653
|
0.001695
|
|
44
|
0.002939
|
0.001879
|
|
45
|
0.003243
|
0.002070
|
|
46
|
0.003563
|
0.002268
|
|
47
|
0.003922
|
0.002486
|
|
48
|
0.004320
|
0.002725
|
|
49
|
0.004749
|
0.002977
|
|
50
|
0.005193
|
0.003245
|
|
51
|
0.005647
|
0.003514
|
|
52
|
0.006122
|
0.003776
|
|
53
|
0.006630
|
0.004029
|
|
54
|
0.007181
|
0.004289
|
|
55
|
0.007779
|
0.004564
|
|
56
|
0.008415
|
0.004875
|
|
57
|
0.009074
|
0.005234
|
|
58
|
0.009727
|
0.005647
|
|
59
|
0.010371
|
0.006103
|
|
60
|
0.011034
|
0.006589
|
|
61
|
0.011738
|
0.007104
|
|
62
|
0.012489
|
0.007665
|
|
63
|
0.013335
|
0.008303
|
|
64
|
0.014319
|
0.009050
|
|
65
|
0.015482
|
0.009953
|
|
66
|
0.016824
|
0.011001
|
|
67
|
0.018330
|
0.012124
|
|
68
|
0.019900
|
0.013250
|
|
69
|
0.021539
|
0.014419
|
|
70
|
0.023396
|
0.015718
|
|
71
|
0.025476
|
0.017201
|
|
72
|
0.027794
|
0.018896
|
|
73
|
0.030350
|
0.020818
|
|
74
|
0.033204
|
0.022996
|
|
75
|
0.036345
|
0.025387
|
|
76
|
0.039788
|
0.028090
|
|
77
|
0.043720
|
0.031225
|
|
78
|
0.048335
|
0.034786
|
|
79
|
0.053650
|
0.038792
|
|
80
|
0.059565
|
0.043109
|
|
81
|
0.065848
|
0.047800
|
|
82
|
0.072956
|
0.053181
|
|
83
|
0.080741
|
0.059365
|
|
84
|
0.089357
|
0.066859
|
|
85
|
0.099650
|
0.075391
|
|
86
|
0.110901
|
0.084744
|
|
87
|
0.123146
|
0.095072
|
|
88
|
0.136412
|
0.106427
|
|
89
|
0.150710
|
0.118857
|
|
90
|
0.166038
|
0.132396
|
|
91
|
0.182374
|
0.147063
|
|
92
|
0.199676
|
0.162859
|
|
93
|
0.217880
|
0.179765
|
|
94
|
0.236903
|
0.197737
|
|
95
|
0.256636
|
0.216706
|
|
96
|
0.276954
|
0.236577
|
|
97
|
0.297713
|
0.257228
|
|
98
|
0.318755
|
0.278515
|
|
99
|
0.339914
|
0.300271
|
|
100
|
1.000000
|
1.000000
|
Progression_RRMS:
|
0
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
EDSS
|
|
0.311
|
0.289
|
0.312
|
0.070
|
0.016
|
0.001
|
0.000
|
0.000
|
0.000
|
0.000
|
0
|
|
0.178
|
0.231
|
0.419
|
0.127
|
0.039
|
0.004
|
0.001
|
0.000
|
0.000
|
0.000
|
1
|
|
0.060
|
0.130
|
0.493
|
0.215
|
0.088
|
0.011
|
0.002
|
0.000
|
0.000
|
0.000
|
2
|
|
0.019
|
0.055
|
0.299
|
0.322
|
0.241
|
0.044
|
0.013
|
0.003
|
0.004
|
0.000
|
3
|
|
0.005
|
0.017
|
0.127
|
0.251
|
0.411
|
0.121
|
0.048
|
0.014
|
0.007
|
0.000
|
4
|
|
0.001
|
0.004
|
0.033
|
0.096
|
0.252
|
0.295
|
0.211
|
0.085
|
0.023
|
0.000
|
5
|
|
0.000
|
0.001
|
0.009
|
0.034
|
0.123
|
0.257
|
0.329
|
0.190
|
0.056
|
0.001
|
6
|
|
0.000
|
0.000
|
0.003
|
0.013
|
0.057
|
0.169
|
0.309
|
0.257
|
0.189
|
0.004
|
7
|
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.995
|
0.005
|
8
|
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
1.000
|
9
|
Progression_SPMS:
|
0
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
EDSS
|
|
0
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0
|
|
0
|
0.769
|
0.154
|
0.077
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
1
|
|
0
|
0.000
|
0.636
|
0.271
|
0.062
|
0.023
|
0.008
|
0.000
|
0.000
|
0.000
|
2
|
|
0
|
0.000
|
0.000
|
0.629
|
0.253
|
0.077
|
0.033
|
0.003
|
0.005
|
0.000
|
3
|
|
0
|
0.000
|
0.000
|
0.000
|
0.485
|
0.350
|
0.139
|
0.007
|
0.018
|
0.000
|
4
|
|
0
|
0.000
|
0.000
|
0.000
|
0.000
|
0.633
|
0.317
|
0.022
|
0.026
|
0.002
|
5
|
|
0
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.763
|
0.190
|
0.045
|
0.002
|
6
|
|
0
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.805
|
0.189
|
0.006
|
7
|
|
0
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.926
|
0.074
|
8
|
|
0
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
0.000
|
1.000
|
9
|
Regimen:
|
Regimen
|
Units Year 1
|
Units Year 2
|
Units Year 3+
|
|
Siponimod
|
1.000
|
1.000
|
1.000
|
|
Alemtuzumab
|
5.000
|
3.000
|
0.000
|
|
Dimethyl fumarate
|
723.500
|
730.500
|
730.500
|
|
Fingolimod
|
365.250
|
365.250
|
365.250
|
|
Glatiramer acetate
|
365.250
|
365.250
|
365.250
|
|
Rebif 22
|
156.000
|
156.000
|
156.000
|
|
Rebif 44
|
156.000
|
156.000
|
156.000
|
|
Avonex
|
52.000
|
52.000
|
52.000
|
|
Betaferon
|
182.625
|
182.625
|
182.625
|
|
Peginterferon beta-1a
|
26.000
|
26.000
|
26.000
|
|
Natalizumab
|
13.000
|
13.000
|
13.000
|
|
Teriflunomide (7mg)
|
10.000
|
10.000
|
10.000
|
|
Teriflunomide (14mg)
|
365.250
|
365.250
|
365.250
|
|
Ocrelizumab
|
4.000
|
4.000
|
4.000
|
|
Supportive care
|
0.000
|
0.000
|
0.000
|
Relapse_rates:
|
EDSS
|
Relapse Rate, RRMS
|
Relapse Rate, SPMS
|
|
0
|
0.71
|
0.00
|
|
1
|
0.73
|
0.00
|
|
2
|
0.68
|
0.47
|
|
3
|
0.72
|
0.88
|
|
4
|
0.71
|
0.55
|
|
5
|
0.59
|
0.52
|
|
6
|
0.49
|
0.45
|
|
7
|
0.51
|
0.34
|
|
8
|
0.51
|
0.34
|
|
9
|
0.51
|
0.34
|
Relapse_RR:
|
Item
|
Rate ratio
|
|
Siponimod
|
0.34
|
|
Alemtuzumab
|
0.28
|
|
Dimethyl fumarate
|
0.53
|
|
Fingolimod
|
0.46
|
|
Glatiramer acetate
|
0.63
|
|
Rebif 22
|
0.70
|
|
Rebif 44
|
0.64
|
|
Avonex
|
0.83
|
|
Betaferon
|
0.65
|
|
Peginterferon beta-1a
|
0.63
|
|
Natalizumab
|
0.31
|
|
Teriflunomide (7mg)
|
0.77
|
|
Teriflunomide (14mg)
|
0.67
|
|
Ocrelizumab
|
0.35
|
|
Supportive care
|
1.00
|
Relapse_values:
|
Relapse
|
Utility
|
Direct cost
|
Indirect cost
|
|
Mild/moderate
|
-0.091
|
2692
|
2339
|
|
Severe
|
-0.302
|
2692
|
2339
|
Risk_of_progression:
|
Regimen
|
Relative risk
|
|
Siponimod
|
0.68
|
|
Alemtuzumab
|
0.42
|
|
Dimethyl fumarate
|
0.62
|
|
Fingolimod
|
0.68
|
|
Glatiramer acetate
|
0.74
|
|
Rebif 22
|
0.81
|
|
Rebif 44
|
0.73
|
|
Avonex
|
0.79
|
|
Betaferon
|
0.66
|
|
Peginterferon beta-1a
|
0.63
|
|
Natalizumab
|
0.56
|
|
Teriflunomide (7mg)
|
0.86
|
|
Teriflunomide (14mg)
|
0.72
|
|
Ocrelizumab
|
0.47
|
|
Supportive care
|
1.00
|
Rx_costs:
|
Regimen
|
Package*
|
WAC Package Cost*
|
Cost per package
|
Discount
|
Multiplier, Year 1
|
Multiplier, Year 2+
|
Default cost, Year 1*
|
Default cost, Year 2+
|
Cost per admin, Year 1
|
Cost per admin, Year 2+
|
|
Siponimod
|
0
|
0
|
68000.00
|
0.00
|
1.00
|
1.00
|
0
|
0
|
0
|
0
|
|
Alemtuzumab
|
10 mg/ 1 ml
|
22903.86 / 1.2 ml
|
22903.86
|
0.05
|
5.00
|
3.00
|
$108,793
|
$65,276
|
694
|
416
|
|
Dimethyl fumarate
|
240 mg
|
7807.45 / 60EA
|
7807.45
|
0.10
|
12.17
|
12.17
|
$85,492
|
$85,492
|
0
|
0
|
|
Fingolimod
|
0.5 mg
|
7857.07 / 30EA
|
7857.07
|
0.10
|
12.17
|
12.17
|
$86,035
|
$86,035
|
0
|
0
|
|
Glatiramer acetate
|
20 mg/ 1 ml
|
1950.00 / 30EA
|
1950.00
|
0.00
|
12.17
|
12.17
|
$23,725
|
$23,725
|
0
|
0
|
|
Rebif 22
|
22 mcg / 0.5 ml
|
7607.64 / 0.5 12EA
|
7607.64
|
0.15
|
13.04
|
13.04
|
$84,295
|
$84,295
|
0
|
0
|
|
Rebif 44
|
44 mcg / 0.5 ml
|
7607.64 / 0.5 12EA
|
7607.64
|
0.15
|
13.04
|
13.04
|
$84,295
|
$84,295
|
0
|
0
|
|
Avonex
|
30 mcg
|
6925.75 / 4EA
|
6925.75
|
0.20
|
13.04
|
13.04
|
$72,226
|
$72,226
|
0
|
0
|
|
Betaferon
|
0.3 mg
|
7596.85 / 14EA
|
7596.85
|
0.35
|
13.04
|
13.04
|
$64,370
|
$64,370
|
0
|
0
|
|
Peginterferon beta-1a
|
125 mcg/ 0.5ml
|
6925.75 / 1 ml
|
6925.75
|
0.10
|
13.04
|
13.04
|
$81,254
|
$81,254
|
0
|
0
|
|
Natalizumab
|
20 mg/ 1 ml
|
6369.30 / 15 ml
|
6369.30
|
0.05
|
13.04
|
13.04
|
$78,877
|
$78,877
|
949
|
949
|
|
Teriflunomide (7mg)
|
7 mg
|
6816.12 / 28EA
|
6816.12
|
0.10
|
13.04
|
13.04
|
$79,968
|
$79,968
|
0
|
0
|
|
Teriflunomide (14mg)
|
14 mg
|
6816.12 / 28EA
|
6816.12
|
0.10
|
13.04
|
13.04
|
$79,968
|
$79,968
|
0
|
0
|
|
Ocrelizumab
|
NA
|
57.08 / 1 mg
|
57.08
|
0.00
|
1200.00
|
1200.00
|
$68,496
|
$68,496
|
489
|
301
|
|
Supportive care
|
0
|
0
|
0.00
|
0.00
|
0.00
|
0.00
|
0
|
0
|
0
|
0
|
SPMS_conversion:
|
Initial EDSS
|
Probability of Transitioning to SPMS
|
|
EDSS 0
|
0.000
|
|
EDSS 1
|
0.003
|
|
EDSS 2
|
0.032
|
|
EDSS 3
|
0.117
|
|
EDSS 4
|
0.210
|
|
EDSS 5
|
0.299
|
|
EDSS 6
|
0.237
|
|
EDSS 7
|
0.254
|
|
EDSS 8
|
0.153
|
|
EDSS 9
|
1.000
|
Weights_2L:
|
Regimen
|
Siponimod
|
Alemtuzumab
|
Dimethyl fumarate
|
Fingolimod
|
Glatiramer acetate
|
Rebif 22
|
Rebif 44
|
Avonex
|
Betaferon
|
Peginterferon beta-1a
|
Natalizumab
|
Teriflunomide (7mg)
|
Teriflunomide (14mg)
|
Ocrelizumab
|
Supportive care
|
|
Siponimod
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Alemtuzumab
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
|
Dimethyl fumarate
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
|
Fingolimod
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Glatiramer acetate
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Rebif 22
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Rebif 44
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Avonex
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Betaferon
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Peginterferon beta-1a
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
0
|
|
Natalizumab
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Teriflunomide (7mg)
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
0
|
|
Teriflunomide (14mg)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Ocrelizumab
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Supportive care
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
Running R Scripts:
Running: script1:
Running: script2:
test
# myFunc <- function() {
# cat("#' ## Title")
# }
#
# myFunc()
#
# test_df <- data.frame(a = rep(5.424, 72))
#
# lookup_tbl <- mtcars %>% dplyr::distinct(wt, .keep_all = T)
#
# microbenchmark::microbenchmark(
# a = look_up(lookup_tbl, wt = 5.424, value = 'gear'),
# b = look_up(lookup_tbl, wt = test_df$a, value = 'gear')
# )
#
# define_params_context <- function(x, strat, grp) {
# dplyr::filter(x,
# (type == 'strategy variable' & identifier == strat) |
# (type == 'group_variable' & identifier == grp) | type == 'parameter'
# ) %>%
# define_parameters()
# }
#
# context_param_names <- dplyr::filter(model$variables, type != 'parameter')$name
#
# the_contexts <- expand.grid(group = model$groups$name, strategy = model$strategies$name)
# first_res <- define_params_context(model$variables, the_contexts$strategy[1], the_contexts$group[1]) %>%
# evaluate(heRomod2:::create_namespace(100,100))
#
# subseq_res <- the_contexts[-1, ] %>%
# rowwise() %>%
# do({
#
# })
# c("group", "strategy"), function(x) {
# param_list <- define_params_context(model$variables, x$strategy, x$group)
# first_context_index <- which(names(param_list) %in% context_param_names)[1]
#
# # Remove variables before first context parameter if any found
# if (!is.na(first_context_index)) {
# param_list <- param_list[-seq_len(first_context_index - 1)]
# }
#
# evaluate(param_list, clone_namespace(first_res))
# })